Quest Diagnostics has provided a saliva-based genetic test to the Scripps Health institute to identify which coronary stent patients will have a poor response to the antiplatelet drug clopidogrel (Plavix). Clopidogrel, in combination with aspirin, is recommended after implantation of a stent, to ...
Please Login to read the full article.
